Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
J Rheumatol
; 42(3): 541-6, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25593242
ABSTRACT
OBJECTIVE:
Rituximab (RTX) has been used to treat many pediatric autoimmune conditions. We investigated the safety and efficacy of RTX in a variety of pediatric autoimmune diseases, especially systemic lupus erythematosus (SLE).METHODS:
Retrospective study of children treated with RTX. Effectiveness data was recorded for patients with at least 12 months of followup; safety data was recorded for all subjects.RESULTS:
The study included 104 children; 50 had SLE. Improvements in corticosteroid dosage, physician's global assessment of disease activity, and SLE-associated markers of disease activity were seen. The incidence of hospitalized infections was similar to previous studies of patients with childhood-onset SLE.CONCLUSION:
RTX can be safely administered to children and appears to contribute to decreased disease activity and steroid burden.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Reumáticas
/
Antirreumáticos
/
Rituximab
/
Lúpus Eritematoso Sistêmico
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article